基于TCGA数据乳腺癌组织UBE2T表达临床意义分析

发布时间：2018-08-24 07:13

【摘要】：目的既往研究发现,泛素结合酶E2T(ubiquitin-conjugating enzyme E2T,UBE2T)在多种肿瘤中表达升高,然而UBE2T在乳腺癌中是否存在高表达及意义尚不清楚。本研究探讨UBE2T表达水平在乳腺癌中的临床意义和可能的机制。方法从癌症基因组图谱(the cancer genome atlas,TCGA)数据库下载正常乳腺组织和乳腺癌组织中UBE2T基因mRNA二代测序数据及临床信息资料,分析UBE2T mRNA表达水平与乳腺癌临床病理学参数的相关性及对预后的影响。采用Cox回归多因素分析探讨影响乳腺癌患者预后的因素,采用基因集富集分析(gene set enrichment analysis,GSEA)方法预测UBE2T可能的调控通路。结果 UBE2T mRNA在乳腺癌组织中表达量为9.28~3 963.54,中位374.18,显著高于正常乳腺组织中UBE2T表达量8.54~216.13,中位40.44,差异有统计学意义(P0.001),而且UBE2T表达水平与乳腺癌患者年龄、分子分型、T分期、TNM分期、雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)状态以及病理类型存在显著相关,均P0.05。进一步分析发现,UBE2T低表达的患者生存预后优于UBE2T高表达的患者,χ~2=7.490,P=0.006。Cox多因素分析结果表明,年龄、分子分型、N分期、M分期和UBE2T表达水平等均是影响乳腺癌患者预后的独立预后因素,P0.05。GSEA分析表明,UBE2T低表达的组织中存在RIGGINS_TAMOXIFEN_RESISTANCE_DN信号通路(FDR=0.199,P0.001)和ERB2_UP.V1_DN路通(FDR=0.235,P0.001)相关基因富集。结论乳腺癌组织中存在UBE2T mRNA水平表达上调,而且UBE2T的表达水平与患者临床病理因素显著相关,其高表达是乳腺癌预后不良因素,其可作为预后判断的分子标记,是潜在的治疗靶点。
[Abstract]:Objective previous studies have found that the expression of ubiquitin-conjugating enzyme E2T (UBE2T) is increased in various tumors. However, it is not clear whether there is a high expression of UBE2T in breast cancer. This study was to investigate the clinical significance and possible mechanism of UBE2T expression in breast cancer. Methods the second generation mRNA sequencing data and clinical information of UBE2T gene from normal breast and breast cancer tissues were downloaded from cancer genome map (the cancer genome atlas,TCGA) database. To analyze the correlation between UBE2T mRNA expression and clinicopathological parameters of breast cancer and its influence on prognosis. Cox regression multivariate analysis was used to investigate the prognostic factors of patients with breast cancer, and the gene set enrichment analysis (gene set enrichment analysis,GSEA) was used to predict the possible regulatory pathway of UBE2T. Results the expression of UBE2T mRNA in breast cancer tissues was 9.28 ~ 3 963.54, with a median of 374.18, which was significantly higher than that in normal breast tissues (8.54 ~ 216.13, P ~ (0.001). The expression level of UBE2T was significantly higher than that in breast cancer patients' age, molecular typing and T stage. Estrogen receptor (estrogen receptor,ER), progesterone receptor (progesterone receptor,PR) and human epidermal growth factor receptor 2 (HER2) were significantly correlated with pathological type (P 0.05). Further analysis showed that the survival prognosis of patients with low expression of UBE2T was better than that of patients with high expression of UBE2T. The analysis of RIGGINS_TAMOXIFEN_RESISTANCE_DN signal pathway (FDR=0.199,P0.001) and ERB2_UP.V1_DN passageway (FDR=0.235,P0.001) related genes in the tissues with low expression of UBE2T by P0.05. GSEA analysis showed that the expression of RIGGINS_TAMOXIFEN_RESISTANCE_DN signal pathway (FDR=0.199,P0.001) and ERB2_UP.V1_DN pathway (FDR=0.235,P0.001) were abundant in the tissues with low expression of UBE2T. Conclusion the expression of UBE2T mRNA is up-regulated in breast cancer, and the expression of UBE2T is related to the clinicopathological factors. The high expression of UBE2T is a poor prognostic factor in breast cancer, and it can be used as a molecular marker to judge the prognosis of breast cancer. Is a potential therapeutic target.
【作者单位】：汕头市中心医院肿瘤放疗科;
【分类号】：R737.9

【相似文献】